Patient results
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Age (y)/Sex | 13/F | 14/F | 15/M | 12/F |
| Symptoms | 6 wk sore throat, odynophagia, voice change, neck mass | 4 mos hoarseness, 1 mo odynophagia, dysphagia | Nasal mass | 3 wk URT symptoms and nasal mass |
| Tumor location | Epiglottis | Epiglottis and glottis | Sinonasal | Sinonasal |
| CT scan results | 3-cm heterogeneously enhancing epiglottic mass necrotic, level II LN | 3-cm heterogeneously enhancing submucosal mass | 3 cm lobulated, moderately enhancing mass left nasal cavity, bony remodeling | 5 × 7-cm moderately enhancing mass, nasal cavity. Bony destruction sinuses, skull base |
| MR imaging results | Isointense with cortex on FSEIR | Isointense with cortex on FSEIR | Isointense with cortex on FSEIR | |
| Surgery | Modified radical neck dissection | Biopsy | Midface degloving; left Caldwell-Luc | Biopsy |
| Histopathology | Undifferentiated carcinoma | Well-differentiated squamous carcinoma | Poorly differentiated squamous carcinoma | Poorly differentiated squamous carcinoma |
| Cytogenetics | 47,XX, +8, t(15;19)(q13;p13.1). | 46,XY, +der(1)t(1;5)(p12;q11.1), −5,del(22)(q11q13) | T(15;19) | |
| EBV | Negative | Negative | Negative | |
| Chemotherapy | Cisplatin, 5-fluorouracil, docetaxel, methotrexate, vinblastine | Cisplatin | VCR/Cytoxan, Adriamycin, etoposide, carboplatin | Carboplatin |
| Radiation | 69 Gy to supraglottis | 70.2 Gy to larynx | 64.4 Gy to nasopharynx | |
| 54.0 Gy to neck nodes | 52.2 Gy to neck nodes | 50.4 Gy to neck nodes | ||
| Clinical course | Disseminated disease. Death 10 mos after diagnosis | Alive at 8 y f/u. Laryngeal scarring, stenosis. Tracheostomy | Disease-free at 8 y f/u | Disseminated disease. Death 3 mos VBIO, VCR after diagnosis |